# OnCo record resolve (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/resolve/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "resolve", "NCT02436668" ;
  schema:name "RESOLVE"@en ;
  schema:alternateName "RESOLVE ibrutinib pancreatic"@en ;
  schema:description "RESOLVE tested the leukaemia drug ibrutinib as a way to reprogramme the immune cells around pancreatic tumours; added to nab-paclitaxel and gemcitabine it shortened the time to progression and cut the chemotherapy patients could tolerate, with no survival gain."@en ;
  schema:url <https://onco.cc/trials/resolve/> ;
  schema:dateModified "2026-09-24"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT02436668>, <https://doi.org/10.1016/j.annonc.2021.01.070> ;
  onco:status "negative" ;
  onco:phase "3" ;
  onco:cancers <https://onco.cc/cancers/pancreatic/>, <https://onco.cc/cancers/metastatic-pdac/> ;
  onco:technologies <https://onco.cc/technologies/cytotoxic-chemotherapy/>, <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/btk/> ;
  onco:drugs <https://onco.cc/drugs/ibrutinib/>, <https://onco.cc/drugs/gemcitabine-nab-paclitaxel/> ;
  onco:companies <https://onco.cc/companies/abbvie/> ;
  onco:terms <https://onco.cc/terms/pancreatic-failed-programmes/> .